Exostatics

Exostatics Pharmaceuticals S.L., a biotech spin-off from the University of Bordeaux, specializes in at-home diagnostic solutions. Established in October 2021, the company focuses on using biological samples such as blood, urine, and saliva to perform initial screenings for specific biomarkers without the need for invasive tests. This approach allows individuals to proactively manage their health from the comfort of their homes, bypassing the need for hospital visits. Exostatics is currently working to bring this technology to market while securing funding. The company has formed strategic partnerships and holds exclusive licensing agreements with CNRS and INSERM. Exostatics serves the healthcare industry, targeting individuals seeking convenient and accessible diagnostic options. The business model revolves around selling diagnostic devices and kits directly to consumers, generating revenue through product sales. The company's technology is particularly relevant for detecting biomarkers like podocalyxin from exosomes in urine, which is significant for conditions such as diabetic nephropathy. Exostatics collaborates with leading experts in science, healthcare, and business to enhance its offerings and expand its market reach.

Keywords: biotech, diagnostics, biomarkers, exosomes, non-invasive, healthcare, licensing, partnerships, diabetic nephropathy, consumer health